FDA Accepts Orasis Pharmaceuticals’ New Drug Application for CSF-1 for the Treatment of Presbyopia 

- Investigational, novel eye drop candidate was assigned PDUFA goal date of October 22, 2023 Ponte Vedra, FL, February 21, 2023 – Orasis Pharmaceuticals, an emerging ophthalmic pharmaceutical company focused…

Continue ReadingFDA Accepts Orasis Pharmaceuticals’ New Drug Application for CSF-1 for the Treatment of Presbyopia